Physician profile
Sue Lim
NPI 1528044146
$3,337.54
in general payments reported to CMS, 2019-2025
26 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $132 · 2021: $104 · 2022: $846 · 2023: $544 · 2024: $647 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $310.34 | 2019-2025 | Clareon, Argos, Tryptyr |
| Abbvie INC. | $305.56 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $251.04 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $211.43 | 2019-2023 | |
| Rxsight INC | $210.38 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Sight Sciences, INC. | $202.20 | 2019-2024 | Tearcare System |
| Bausch & Lomb Americas INC. | $192.90 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $190.98 | 2019-2023 | |
| Oyster Point Pharma, INC. | $189.40 | 2023-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $172.77 | 2022-2025 | Cequa, Xelpros |
| Shire North American Group INC | $130.84 | 2019 | |
| Biotissue Holdings INC. | $124.21 | 2021-2025 | |
| Allergan, INC. | $115.51 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $111.69 | 2023 | Artevo 800 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $89.31 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $83.03 | 2022-2025 | Tecnis Iol, Catalys System |
| Dompe US, INC. | $73.21 | 2019-2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $64.54 | 2019-2022 | |
| Thea Pharma INC. | $62.53 | 2022-2025 | Iyuzeh |
| Harrow Eye, LLC | $50.33 | 2025 | Vevye, Iheezo |
| Eyevance Pharmaceuticals LLC | $48.84 | 2020-2022 | |
| Amgen INC. | $46.94 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $40.72 | 2022-2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $31.60 | 2019 | |
| Aerie Pharmaceuticals, INC. | $13.62 | 2019 | |
| Ocular Therapeutix, INC. | $13.62 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.